Storage and Handling for the M-M-R<sup>®<sup><sub>II</sub> Vaccine

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Storage and Handling for the
M-M-R®II Vaccine

Storage and Handling for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine

Storage and Handling

  • If you have questions about the condition of the vaccine at the time of delivery, you should immediately place vaccine in recommended storage and call the Merck Vaccine Customer Center at 877.VAX.MERCK (877.829.6372).

Storage

  • Exposure to light may inactivate the vaccine viruses.
  • To maintain potency, M-M-R®II must be stored between -58°F and +46°F (-50°C to +8°C).
  • Use of dry ice may subject M-M-R®II to temperatures colder than -58°F (-50°C).
  • Before reconstitution, refrigerate the lyophilized vaccine at 36°F to 46°F (2°C to 8°C).
  • Store accompanying diluent in the refrigerator (36°F to 46°F, 2°C to 8°C) or at room temperature (68°F to 77°F, 20°C to 25°C). DO NOT FREEZE the diluent.
  • Administer M-M-R®II vaccine as soon as possible after reconstitution. If not administered immediately, reconstituted vaccine may be stored between 36°F to 46°F (2°C to 8°C), protected from light, for up to 8 hours. Discard reconstituted vaccine if it is not used within 8 hours.
Storage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

Handling

  • To reconstitute, use only the diluent supplied with the vaccine since it is free of preservatives or other antiviral substances which might inactivate the vaccine.
  • Withdraw the entire volume of the supplied diluent from its vial and inject into lyophilized vaccine vial. Agitate to dissolve completely. Discard if the lyophilized vaccine cannot be dissolved.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Visually inspect the vaccine before and after reconstitution prior to administration. Before reconstitution, the lyophilized vaccine is a light yellow compact crystalline plug, when reconstituted, is a clear yellow liquid. Discard if particulate matter or discoloration are observed in the reconstituted vaccine.
  • For information regarding the product or questions regarding storage conditions, call 1-800-MERCK-90 (1-800-637-2590).
It Is Recommended That the M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Vaccine Be Used as Soon as Possible After Reconstitution

General Tips

  • Ensure that the refrigerator is plugged into an outlet in a protected area where it cannot be disconnected accidentally.1
  • Use a sterile syringe free of preservatives, antiseptics, and detergents for each injection and/or reconstitution of the vaccine because these substances may inactivate the live virus vaccine.
  • For general questions concerning the proper storage and handling of Merck vaccines, please contact the Merck Vaccine Customer Helpline at 800.MERCK.90 (800.637.2590), Monday through Friday, 8:00 AM to 7:00 PM ET.

General Tips for Merck Vaccine Administration

ref1

Reference

  1. Centers for Disease Control and Prevention (CDC). Vaccine storage and handling toolkit. https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit-2020.pdf. Published January 2020. Accessed January 8, 2020.
cdc

You are about to leave MerckVaccines.com

CDC Information

Thank you for visiting.

Merck does not review or control the content at the site to which this link connects. Merck makes no representation with respect to the content of any non-Merck site.

Indications and Usage for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; family history of congenital or hereditary immunodeficiency; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; family history of congenital or hereditary immunodeficiency; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

US-MMR-00073 09/20